The story of the erectile dysfunction drug presents a intricate picture for shareholders. While the initial launch generated massive gains, the end of its patent opened the door to generic competitors, dramatically https://socialwebconsult.com/story7140189/viagra-and-big-pharma-a-volatile-investment